These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension]. Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623 [No Abstract] [Full Text] [Related]
3. Are there unintended consequences of step-therapy programs? Cox ER; Seiz BJ Am J Manag Care; 2009 Sep; 15(9):654, 656; author reply 656. PubMed ID: 19747030 [No Abstract] [Full Text] [Related]
5. Angiotensin receptor blockers: impact on costs of care. Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456 [TBL] [Abstract][Full Text] [Related]
6. NIH promotes use of lower cost drugs for hypertension. Spurgeon D BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483 [No Abstract] [Full Text] [Related]
7. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Pittman DG; Tao Z; Chen W; Stettin GD Am J Manag Care; 2010 Aug; 16(8):568-76. PubMed ID: 20712390 [TBL] [Abstract][Full Text] [Related]
8. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies]. Rorive G; Delporte JP Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395 [TBL] [Abstract][Full Text] [Related]
9. Cost of hypertension treatment and the price of health. Menard J; Cornu P; Day M J Hum Hypertens; 1992 Dec; 6(6):447-58. PubMed ID: 1296008 [No Abstract] [Full Text] [Related]
10. Differences in medical expenditure according to drug prices. Ueshima H Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148 [No Abstract] [Full Text] [Related]
12. Relative costs of antihypertensive drug treatment. Strasser T J Hum Hypertens; 1992 Dec; 6(6):489-94. PubMed ID: 1296015 [No Abstract] [Full Text] [Related]
13. [Pharmacotherapy of hypertension. How much can safely be saved?]. Anlauf M MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022 [No Abstract] [Full Text] [Related]
15. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. Hilleman DE J Manag Care Pharm; 2014 Jan; 20(1):93-100. PubMed ID: 24372463 [No Abstract] [Full Text] [Related]
16. [Economy, costs and drug choices in cardiology. A reflection on the 2012 position paper of the Italian Society of Hypertension]. Camerini F; Palcic S G Ital Cardiol (Rome); 2013 Jun; 14(6):412-5. PubMed ID: 23748537 [No Abstract] [Full Text] [Related]
17. Compliance with antihypertensive therapy: raising the bar of expectations. Rudd P Am J Manag Care; 1998 Jul; 4(7):957-66. PubMed ID: 10181995 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacoeconomic aspects of the treatment of essential hypertension]. Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090 [No Abstract] [Full Text] [Related]
19. Health economic issues and the future treatment and management of hypertension. Giles TD AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589 [No Abstract] [Full Text] [Related]